RxDoctor Payments DataLook up a doctor →

Lana Melendres Groves, MD

Pulmonary Disease · Albuquerque, NMNPI 1548309537

Payments from drug & device makers

$3,268,667in general payments, 2019–2025

Across 1,242 payments — averaging $2631.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.6M
  • United Therapeutics Corporation$917K
  • Actelion Pharmaceuticals US, Inc.$290K
  • Actelion Pharmaceuticals, Ltd$131K
  • Bayer$117K
  • Sumitomo Pharma America, Inc.$111K
  • plus $92K from 7 others

What the payments were for

  • Consulting fees$350,39032%
  • Speaking & faculty fees$613,83256%
  • Travel & lodging$106,91610%
  • Food & beverage$24,0122%
  • Education$920%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,268,667 in reported general payments places this provider in the 95th percentile of 56 pulmonary disease providers in New Mexico.

See all pulmonary disease providers in New Mexico

Medicare billing

Part B allowed, 2024
$17,321
Medicare patients
109
Services billed
213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan58$726,103
Tyvaso DpiTreprostinil14$327,961
AdempasRiociguat16$201,725
Ambrisentan23$94,204
AdcircaTadalafil12$49,237
Sildenafil Citrate18$46,123
Tadalafil49$17,610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$290,102$726,10358 claims
BayerAdempas$117,415$201,72516 claims
United Therapeutics CorporationAdcirca$917,125$49,23712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 56 pulmonary disease providers in New Mexico.

Other pulmonary disease in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →